DINA-004 + DINA-005

DINA-004 and DINA-005 are preclinical gene therapy candidates being developed by DiNAQOR for the treatment of dilated cardiomyopathy (DCM). These programs leverage DiNAQOR's specialized genetic medicine platform, which utilizes engineered gene-vector-promoter constructs designed for cardiac-specific expression. A key feature of these therapies is the use of a proprietary loco-regional delivery system intended to deliver the genetic material directly to the heart muscle. This approach is designed to maximize the transduction of cardiac cells while minimizing systemic exposure and potential off-target effects in other organs. While the specific biological targets for DINA-004 and DINA-005 have not been publicly disclosed, they are part of a pipeline focused on addressing the underlying genetic causes of cardiomyopathies and heart failure.